China Launches 2000-Person Stem Cell Trial to Combat Age-Related Decline
Beijing's 301 Hospital begins recruiting adults 50+ for the world's largest stem cell antiaging clinical trial using an already-approved therapy.
Summary
China's top military hospital, 301 Hospital in Beijing, has launched the country's first large-scale clinical trial testing whether stem cells can slow age-related physical decline. The trial will enroll 2,000 adults aged 50 and older across multiple centers. The treatment, called amimestrocel (brand name Ruibosheng), uses mesenchymal stem cells from umbilical cord tissue. It was already approved in China in early 2025 for a serious transplant complication, giving researchers a safety foundation to build on. Scientists hope to find out whether stem cells can reduce inflammation and support tissue repair broadly enough to preserve physical function and quality of life as people age — a preventive approach rather than treating diseases one at a time.
Detailed Summary
China is confronting a rapidly aging population, and one of its most prestigious medical institutions is responding with an ambitious clinical trial. Beijing's 301 Hospital has begun recruiting 2,000 adults aged 50 and older for what is described as China's first large-scale randomized controlled trial evaluating stem cells as an antiaging intervention. The scale and design of this study represent a meaningful step forward for a field that has long struggled to separate genuine science from hype.
The therapy under investigation is amimestrocel, sold as Ruibosheng, which uses mesenchymal stem cells derived from human umbilical cord tissue. These cells are thought to help regulate inflammation and support tissue repair — two biological processes that deteriorate with age and underlie many chronic diseases. Crucially, this is not an experimental unknown: the drug received conditional approval from China's National Medical Products Administration in January 2025 for treating acute graft-versus-host disease, and has since been used in over 70 transplant centers.
The trial takes a paradigm-shifting approach to aging medicine. Rather than waiting for diseases like diabetes, heart disease, or dementia to appear and treating them separately, researchers are asking whether a single biological intervention can strengthen the body's resilience before serious decline sets in. This preventive framing — maintaining function rather than repairing damage — reflects the broader philosophy driving modern longevity science.
The multicenter randomized controlled design adds credibility. This is not a small pilot or an observational study; it is built to generate statistically meaningful evidence about whether stem cell therapy produces real-world functional benefits in aging adults.
Caveats remain significant. Results are years away, the trial is based in China with regulatory contexts different from Western markets, and conditional drug approval does not equal proven antiaging efficacy. Independent replication will be essential before this becomes a globally adopted intervention.
Key Findings
- 2,000 adults aged 50+ are being enrolled in China's first large-scale stem cell antiaging randomized controlled trial.
- The therapy, amimestrocel, uses umbilical cord mesenchymal stem cells already approved in China for a transplant complication.
- Mesenchymal stem cells may reduce chronic inflammation and support tissue repair, two key drivers of biological aging.
- The trial uses a preventive framing — preserving function before disease appears — rather than treating individual conditions.
- Over 70 Chinese transplant centers have already used this therapy, providing a real-world safety dataset.
Methodology
This is a news report from Longevity.Technology summarizing an announced clinical trial at 301 Hospital in Beijing. The source cites official information from the PLA General Hospital and references China's National Medical Products Administration approval. No peer-reviewed data from the trial itself is yet available, as recruitment has just begun.
Study Limitations
The trial results are years away and no efficacy data for antiaging applications exists yet. China's conditional drug approval process differs from FDA or EMA standards, requiring independent validation. The article is a news summary without access to the full trial protocol, endpoints, or conflict-of-interest disclosures.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.